anorexia-cachexia

anorexia-cachexia

 
a systemic response to cancer occurring as a result of metabolites which may be produced by the tumor cells and released into the blood stream, stimulating the satiety center in the hypothalamus and producing appetite loss, gross alterations of metabolic patterns, and a profound systemic confusion which may result in further anorexia. This leads to malnutrition, weight loss, muscular weakness, and a negative nitrogen balance that contributes to the development of cachectic wasting.
References in periodicals archive ?
As compared to participants without weight loss, study participants with weight loss reported significantly lower overall quality of life, worsened anorexia-cachexia symptoms and concerns, and higher symptomology, specifically fatigue, nausea and appetite loss.
Anamorelin is a new first-in-class, oral, once daily drug, presently in phase III for the treatment of anorexia-cachexia in NSCLC, a detrimental multifactorial disorder that affects more than 50 percent of people with cancer and in which systemic inflammation, reduced food intake and altered metabolism contribute to loss of muscle mass and reduction of body weight leading to reduced quality of life, functional impairment and decreased survival.
22) Cytokines have been reported to influence the balance of orexigenic and anorexigenic circuits that predispose to cancer anorexia-cachexia syndrome.
Cancer anorexia-cachexia syndrome: cytokines and neuropeptides.
Management of anorexia-cachexia associated with cancer and HIV infection.
This approval will allow the company to commence clinical trials in patients with histologically confirmed malignancies who present with clinically demonstrable anorexia or anorexia-cachexia syndrome.
The studies assessed the efficacy and safety of the ghrelin receptor agonist anamorelin in patients with Cancer Anorexia-Cachexia and non-small cell lung cancer (NSCLC).
Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announces that on February 19th the journal, The Lancet Oncology, published the results from the pivotal ROMANA Phase III trials assessing efficacy and safety of the ghrelin receptor agonist anamorelin in patients with Cancer Anorexia-Cachexia in non-small cell lung cancer (NSCLC).
Anamorelin is a novel, once-daily, orally active ghrelin receptor agonist in development for the treatment of Cancer Anorexia-Cachexia in patients suffering from non-small cell lung cancer (NSCLC), an area of significant unmet medical need.
Anamorelin is a new first-in-class, oral, once daily drug, currently in phase III for the treatment of anorexia-cachexia in NSCLC, a detrimental multifactorial disorder that affects over 50% of people with cancer and in which systemic inflammation, reduced food intake and altered metabolism contribute to loss of muscle mass and reduction of body weight leading to reduced quality of life, functional impairment and decreased survival.
At present, in Anamorelin is a new first-in-class, oralc, in phase III for the treatment of anorexia-cachexia in NSCLC, a detrimental multifactorial disarray that affects over 50% of people with cancer and in which systemic inflammation, reduced food intake and altered metabolism contribute to loss of muscle mass and reduction of body weight leading to reduced quality of life.